Physician profile
Bal Reddy
NPI 1043241268
$993.15
in general payments reported to CMS, 2019-2025
11 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $35.58 · 2021: $130 · 2022: $154 · 2023: $46.05 · 2024: $234 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $240.28 | 2021-2023 | Watchman Access System |
| Madrigal Pharmaceuticals | $147.49 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals Lp | $125.01 | 2024 | Airsupra |
| Radius Health, INC. | $124.72 | 2019 | |
| Gilead Sciences, INC. | $121.82 | 2025 | Yeztugo |
| Viiv Healthcare Company | $108.99 | 2024 | |
| Lilly USA, LLC | $42.67 | 2022-2023 | Mounjaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.58 | 2020 | |
| Acist Medical Systems, INC. | $17.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.30 | 2021 | |
| Dexcom, INC. | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bal Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.